CollPlant Biotechnologies (CLGN) Total Non-Current Liabilities (2017 - 2025)
CollPlant Biotechnologies (CLGN) posted Total Non-Current Liabilities of $2.0 million for Q4 2025, down 5.58% on a QoQ basis from $2.2 million in Q3 2025, and down 10.68% year-over-year from $2.3 million in Q4 2024.
CollPlant Biotechnologies (CLGN) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $2.0 million for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 10.68% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 10.68% YoY) and the FY2025 annual result came in at $2.0 million, down 10.68% from the prior year.
- Total Non-Current Liabilities was $2.0 million for Q4 2025 at CollPlant Biotechnologies, down from $2.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $3.1 million in Q4 2021 and bottomed at $2.0 million in Q4 2025.
- A 5-year average of $2.5 million and a median of $2.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Peak annual rise in Total Non-Current Liabilities reached 11.77% in 2022, while the deepest fall reached 22.89% in 2022.
- CollPlant Biotechnologies' Total Non-Current Liabilities stood at $3.1 million in 2021, then retreated by 22.89% to $2.4 million in 2022, then climbed by 6.42% to $2.5 million in 2023, then declined by 10.26% to $2.3 million in 2024, then dropped by 10.68% to $2.0 million in 2025.
- Business Quant data shows CLGN's Total Non-Current Liabilities at $2.0 million in Q4 2025, $2.2 million in Q3 2025, and $2.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 2.42 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Sep 30, 2023 | 2.53 Mn |
| Jun 30, 2023 | 2.75 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 2.42 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 2.92 Mn |
| Dec 31, 2021 | 3.09 Mn |
| Sep 30, 2021 | 2.64 Mn |
| Jun 30, 2021 | 2.65 Mn |
| Mar 31, 2021 | 2.61 Mn |
| Dec 31, 2020 | 2.98 Mn |